Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07262190

NavSTAR Implementation Effectiveness Trial Across a Health System

Patient Navigation (PN) interventions following hospitalization can improve outcomes for people with opioid use disorder treatment. Delivering PN interventions on a wide scale requires many resources and coordination across institutions. This will use an evidence-based process to find solutions to these significant barriers by engaging community, hospital, and patient partners. This study is being conducted to learn more about how to implement NavSTAR, a patient navigation intervention for people with opioid use disorder, across a health system. The research team showed in a previous study with 400 participants that NavSTAR significantly increased entry into opioid use disorder treatment, reduced readmissions to the hospital, and was highly cost- effective compared to treatment as usual. This study will first pilot NavSTAR with 32 patient participants across 4 hospitals in the City of Philadelphia. Then, a large trial with 720 patient participants will be conducted to see if people who need the intervention are reached, and a sustainable plan will be created to continue the intervention after the grant award period.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jefferson Health

Philadelphia, Pennsylvania, 19107, United States

Location status: Recruiting

Location contact

Karen Alexander, PhD

CONTACT

[email protected]

267-398-3560

About this study

Opioid agonist treatment (OAT) is protective against overdose, yet less than 20% of people with opioid use disorder (OUD) engage in such treatment. Hospital utilization is high among people with OUD and can be a 'reachable moment' to initiate OAT. However, most hospitals lack the capacity to follow up with patients after discharge. Patient navigation (PN) interventions following hospital discharge can help patients engage in OAT and navigate complex systems of care. However, challenges persist in implementing PN interventions on a wide scale, as they require coordination across organizations, data sharing, dedicated personnel, and resources. To bring these interventions to scale, strategies are needed to determine feasibility, reach, and sustainability. Testing innovative implementation strategies for PN interventions has the potential for significant impact, as it will demonstrate implementation success of an intervention that can address the opioid epidemic in real-world settings and close the research-to-practice translation gap. The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services to Avoid Rehospitalization (NavSTAR). The research team showed in a single-site randomized trial with 400 participants that NavSTAR significantly improved OAT entry, reduced readmissions, and was highly cost-effective compared to treatment as usual. The present study will test an Implementation Facilitation (IF) strategy to provide training, resources, and performance feedback to implement NavSTAR in five hospitals in Philadelphia. It is hypothesized that engaging stakeholders in an IF strategy will yield an implementation process that is feasible, acceptable, and effective in improving outcomes for patients with OUD. During the R33 phase, a type II hybrid-implementation-effectiveness trial of NavSTAR will be conducted with 720 participants using a randomized stepped-wedge design.

The proposed study is a type II hybrid implementation-effectiveness trial of Navigation Services to Avoid Rehospitalization (NavSTAR). The present study will test an Implementation Facilitation (IF) strategy following Proctor's conceptual model of implementation, using an external facilitator and internal local clinical champions to provide training, resources and performance feedback to implement NavSTAR in five hospitals. It is hypothesized that engaging stakeholders in an IF strategy will yield an implementation process that is feasible, acceptable, and effective in expanding engagement in OAT post-discharge. This type II hybrid implementation-effectiveness randomized stepped-wedge trial (N=720) will examine NavSTAR's sustained use in a hospital system to improve outcomes for patients with OUD.

R33 Specific Aims:

  • Aim 1: Determine the successful implementation of NavSTAR in terms of a) feasibility, b) reach, and c) sustainability using the newly developed hospital system protocol.
  • Aim 2: Determine the effectiveness of NavSTAR to a) improve OAT initiation in the three months post-discharge, b) decrease hospital utilization (inpatient readmissions and emergency department visits), c) reduce overdoses (fatal and non-fatal), and d) improve other patient outcomes (e.g., quality of life, substance use).

The proposed study has high public health significance because it will develop and test an implementation strategy for an intervention (NavSTAR) to improve OAT engagement and outcomes for patients with OUD. The study will yield novel data on how best to implement NavSTAR across a health system operating in an epicenter of the OUD crisis. Study findings will help to develop a path to scale-up this important intervention to address the opioid epidemic.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 or older;
  • current DSM-5 criteria for moderate to severe OUD;
  • willing and able to provide informed consent in English.

Exclusion criteria

  • enrollment in OUD treatment 30-days prior to hospitalization;
  • residency outside the City of Philadelphia;
  • pregnancy;
  • planned discharge to a long-term inpatient care facility (e.g., hospice);
  • hospitalization for a suicide attempt.

Treatment and study plan

NavSTAR (Philly adaptation)

Behavioral

NavSTAR consists of TAU plus contact with a trained patient navigator who delivers the NavSTAR intervention, inclusive of theory-based motivational content, during and after discharge from the hospital. The patient navigator also has access to a small participant fund to assist with overcoming structural barriers to care (e.g., phone, obtaining IDs, a meal, a taxi ride etc.). Using the NavSTAR PN manual, the PN will address internal and external barriers to engagement in OAT through motivational intervention techniques and proactive case management and care coordination services. Contact with the PN begins at the bedside while the participant is admitted to the hospital and continues for 3 months after discharge

Primary outcomes

  1. Rate of Opioid Agonist Treatment initiation

    Time frame: 3 months

    Post-discharge rate of OAT initiation will be ascertained via health record review and self-report with verification through records where applicable (e.g., Community Behavioral Health system).

Secondary outcomes

  1. Feasibility: Demonstrated ability to enroll participants in the intervention

    Time frame: From baseline until end of study, approximately 30 months

    Feasibility will be measured based on the number of participants who received the intervention during the implementation period.

  2. Inpatient readmissions (30 days)

    Time frame: 30 days

    Information on acute care hospital inpatient readmission within 30 days will be assessed using health records and self-report (in the event of inconsistency, objective data will dominate).

  3. Inpatient readmissions

    Time frame: through 3, 6, and 12 months

    Inpatient hospital readmissions (number of events) will be assessed using health record review and self-report (in the event of inconsistencies, objective data will dominate).

  4. Emergency department visits

    Time frame: through 3, 6, and 12 months

    Emergency Department utilization (number of events) will be assessed via health record review and self-report (in the event of inconsistency, objective data will dominate).

  5. Self-reported days of opioid use in the past 30 days

    Time frame: Baseline to 3-, 6-, and 12-months

    Self-reported days of non-prescribed opioid use in the past 30 days will be assessed at each interview.

  6. Opioid use

    Time frame: 3-, 6-, and 12-month follow-up

    Positive oral fluid test for non-prescribed opioids (e.g., fentanyl, heroin, etc.)

  7. Overdose events

    Time frame: through 3, 6, and 12 months

    Overdose events will be assessed by self-report and health records (for non-fatal events) and death records (for fatal events)

  8. Changes in Social Support from Baseline to Follow-up

    Time frame: Baseline to 3-, 6-, and 12-month follow-up

    Social support will be measured using the Social Support Scale to determine the extent to which services influenced social support. It is a numeric scale from 0 to 100, with higher scores indicating greater social support.

  9. Changes in Quality of Life from Baseline to Follow-up

    Time frame: Baseline to 3-, 6-, and 12-month follow up

    Quality of life will be measured via the World Health Organization Quality of Life instrument. It is a numeric scale with scores possible from 4-20, with higher scores indicating higher quality of life.

  10. Changes in Psychological distress from baseline

    Time frame: Baseline to 3-, 6- and 12-month follow-up

    Kessler Psychological Distress Scale will be used to assess how participants have been feeling (nervous, hopeless, restless, depressed, worthless, etc) during their last 30 days. It is a numeric scale with scores ranging from 0 to 24, with higher scores indicating greater psychological distress.

Other outcomes

  1. Rate of Patient-Directed Discharge

    Time frame: At discharge (assessed up to 12 months)

    Patient-directed discharge from the index hospitalization (i.e., "against medical advice") will be determined by health record review.

  2. Mortality

    Time frame: through 12 months

    Mortality will be tracked from participant monitoring and death records

Study contacts

Contact information is provided by the study sponsor or research team.

Jan Gryczynski, PhD

CONTACT

[email protected]

443-676-4219

Karen Alexander, PhD

CONTACT

[email protected]

2673983560

Sponsors and collaborators

Lead sponsor

Friends Research Institute, Inc.

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)
  • Thomas Jefferson University

Registry information

Official study title

Implementing a Patient Navigation Intervention Across a Health System to Improve Outcomes for Patients With Opioid Use Disorder

Acronym: Philly NavSTAR

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Dec 3, 2025
Registry last updated
Dec 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.